

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 7885.55USWO	Application Number: 09/125,751
	Applicant: FODSTAD et al.	
	Filing Date: October 30, 1998	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
EM		"Making the most of mucin: a novel target for tumor immunotherapy", Barratt-Boyes SM, Cancer Immunol Immunother. 1996 Nov; 43(3): 142-51.
		"The Epithelial Glycoprotein 2 (EGP-2) Promoter-driven Epithelial-specific Expression of EGP-2 in Transgenic Mice: A New Model to Study Carcinoma-directed Immunotherapy", McLaughlin et al., Cancer Research 61, 4105-4111, May 15, 2001.
		"Selection and Characterization of Anti-MUC-1 scFvs Intended for Targeted Therapy", Winthrop et al., Clinical Cancer Research, Vol. 9, 3845s-3853s, September 1, 2003 (Suppl.).
		"Kinetics of Uptake and Degradation of an Abrin Immunotoxin by Melanoma Cells and Studies of the Rates of Cellular Intoxication", Godal et al., Int. J. Cancer: 42, 400-404 (1988).
		"Studies on the Mechanism of Action of Abrin-9.2.27 Immunotoxin in Human Melanoma Cell Lines", Godal et al., Cancer Research 47, 6243-6247, December 1, 1987.
		"Systematic Immunotoxin Treatment Inhibits Formation of Human Breast Cancer Metastasis and Tumor Growth in Nude Rats", Engebraaten et al., Int. J. Cancer: 88, 970-976 (2000).
		"A Murine cDNA Encodes a Pan-Epithelial Glycoprotein that is also Expressed on Plasma Cells", Bergsagel et al., The Journal of Immunology, Vol. 148, 590-596, No. 2, January 15, 1992.
		"Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2", Szala et al., Proc. Natl. Acad. Sci. USA, Vol. 87, pp. 3542-3546, May 1990 Biochemistry.
		"Molecular Cloning and Characterization of a Human Adenocarcinoma/Epithelial Cell Surface Antigen Complementary DNA", Strnad et al., Cancer Research 49, 314-317, January 15, 1989.
		Appendix 3-6, "Monoklonaler Antikörper BM7" and Appendix 3-7, "Monoklonaler Antikörper BM2", Brummend et al., Cancer Research, 1994, 54: 4162-4168
		"Pharmacokinetics and Scintigraphy of Indium-111-DTPA-MOC-31 in Small-Cell Lung Carcinoma", Kosterink et al., The Journal of Nuclear Medicine- Vol. 36, No. 12, December 1995.
		"Can therapeutic concentrations of the anti EGP2 immunotoxin conjugate MOC31-PE be achieved in patients with antigen positive carcinomas? A phase I study in patients with advanced mammary, lung, colorectal or prostate carcinoma", Aamdal et al., pp. 1-24.

EXAMINER <i>L. Ga</i>	DATE CONSIDERED <i>6/17/06</i>
-----------------------	--------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.